Vascular Biogenics Ltd. (NasdaqGM: VBLT) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Vascular Biogenics Ltd. operating as VBL Therapeutics, (the “Company”) (NasdaqGM: VBLT) with Notable Labs, Inc. Under the terms of the proposed transaction, Vascular shareholders will end up owning approximately 24% of the combined company, each on a fully-diluted basis and subject to adjustment. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.